
    
      This study was an open-label, multicenter, activity, safety, tolerability, and PK study of
      KX2-391 Ointment administered topically to the face or scalp of participants with AK.

      The study consists of Screening, Treatment, and Follow-up Periods. Eligible participants were
      received 3 or 5 consecutive days of topical treatment, applied at the study site. Blood
      samples for PK analysis were collected. Activity (lesion counts) and safety evaluations were
      performed.
    
  